Epstein-Barr virus latent antigen-Major Histocompatibility Complex (EBV-pMHC)

The Epstein-Barr virus (EBV) antigen-Major Histocompatibility Complex (EBV-pMHC) is a specialized molecular target found on the surface of EBV-infected and transformed cells (Source: Taylor et al., 2015, JEM). It comprises viral peptides derived from latent proteins—specifically Latent Membrane Protein 1 (LMP1), Latent Membrane Protein 2 (LMP2), and Epstein-Barr Nuclear Antigen 1 (EBNA1)—bound to Major Histocompatibility Complex (MHC) molecules (Source: Young & Rickinson, 2004, Nature Reviews Cancer). These complexes are essential for the immune system to recognize cells harboring the EBV genome, which is associated with various malignancies including Nasopharyngeal Carcinoma and Post-Transplant Lymphoproliferative Disorder (Source: Cohen et al., 2011, J. Gen. Virol.). In EBV-associated cancers, these viral proteins drive oncogenesis by mimicking cellular signaling pathways or maintaining the viral episome. Therapeutic interventions like Tabelecleucel utilize EBV-specific T-cells to recognize these pMHC targets and induce apoptosis in tumor cells (Source: Prockop et al., 2020, JCI). The high specificity of these viral antigens makes them ideal targets for immunotherapy, as they are absent in healthy, non-infected human tissues. However, the effectiveness of such therapies is often limited by the specific HLA alleles of the patient, requiring HLA-matched donor cells or broad-spectrum T-cell products (Source: Bollard & Heslop, 2016, Blood). Monitoring EBV DNA levels and the expression of these specific latent antigens serves as a vital biomarker strategy for treatment efficacy.

Other names

EBV peptide-HLA complexLMP1/LMP2/EBNA1-MHC complexEpstein-Barr virus-specific peptide-MHCEBV-associated pMHCEBV-LMP/EBNA-MHC complex

Targeted recognition of viral peptides presented by MHC molecules by T-cell receptors (TCRs), leading to the activation of cytotoxic pathways and lysis of EBV-positive cells (Source: Prockop et al., 2020, JCI).